サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1402892

ペプチド治療薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年

Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 257 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ペプチド治療薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年
出版日: 2023年11月28日
発行: Transparency Market Research
ページ情報: 英文 257 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ペプチド治療薬市場- レポートの範囲

世界のペプチド治療薬市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、2017年から2031年の期間、2023年を基準年、2031年を予測年とみなし、世界のペプチド治療薬市場の収益を提供します。このレポートは、2023年から2031年までの世界のペプチド治療薬市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、ペプチド治療薬市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 378億米ドル
2031年の市場価値 859億米ドル
CAGR 9.6%

このレポートは、世界のペプチド治療薬市場の競合情勢を詳しく調査しています。世界のペプチド治療薬市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のペプチド治療薬市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2023～2031年

第5章 重要な洞察

  • 2022年にFDA承認
  • 2000年以降に承認されたペプチド医薬品とその標的および適応症
  • ホワイトスペース分析
  • ポーターの分析
  • パイプライン分析
  • ペプチド医薬品の化学構造傾向解析
  • ペプチド医薬品に使用される分離媒体
  • COVID-19の影響分析

第6章 世界市場の分析と予測：製品タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 製品タイプ別の市場金額予測、2023～2031年
    • 革新的
    • ジェネリック
  • 製品タイプ別の市場の魅力

第7章 世界市場の分析と予測：用途別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 用途別の市場金額予測、2023～2031年
    • 代謝
    • 腫瘍
    • 胃腸
    • 心血管
    • 神経
    • その他
  • 用途別の市場の魅力

第8章 世界市場の分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 投与経路別の市場金額予測、2023～2031年
    • 非経口
    • 経口
    • その他
  • 投与経路別の市場の魅力

第9章 世界市場の分析と予測：ペプチドの種類別

  • イントロダクションと定義
  • 主な調査結果/発展
  • ペプチドの種類別の市場金額予測、2023～2031年
    • 天然ペプチド
    • 類似ペプチド
    • 異種ペプチド
  • ペプチドの種類別の市場の魅力

第10章 世界市場の分析と予測：技術別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 技術別の市場金額予測、2023～2031年
    • 液相
    • 固相
    • ハイブリッド
  • 技術別の市場の魅力

第11章 世界市場の分析と予測：製造タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 製造タイプ別の市場金額予測、2023～2031年
    • 社内
    • CMO
  • 製造タイプ別の市場の魅力

第12章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 地域別の市場金額予測
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 国・地域別の市場の魅力

第13章 北米市場の分析と予測

第14章 欧州市場の分析と予測

第15章 アジア太平洋市場の分析と予測

第16章 ラテンアメリカ市場の分析と予測

第17章 中東・アフリカ市場の分析と予測

第18章 競合情勢

  • 市場プレーヤー-競合マトリックス（企業の階層および規模別）
  • 企業別市場シェア分析（2022）
  • 企業プロファイル
    • Amgen, Inc.
    • Sachem Holding AG
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
図表

List of Tables

  • Table 01: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 02: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 03: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 04: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
  • Table 05: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 06: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, Manufacturing Type, 2023-2031
  • Table 07: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Region, 2023-2031
  • Table 08: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 09: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 10: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 11: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 12: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
  • Table 13: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 14: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
  • Table 15: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 16: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 17: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 18: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 19: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
  • Table 20: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 21: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
  • Table 22: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 23: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 24: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 25: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 26: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
  • Table 27: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 28: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
  • Table 29: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 30: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 31: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 32: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 33: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Type of Peptide, 2023-2031
  • Table 34: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 35: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
  • Table 36: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 37: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 38: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 39: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 40: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Type of Peptide, 2023-2031
  • Table 41: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 42: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
  • Table 43: Global Peptide Therapeutics Market: Company Share Analysis, 2022

List of Figures

  • Figure 01: Global Peptide Therapeutics Market Size, by Application, 2022
  • Figure 02: Peptide Therapeutics Market share (%), by Application, 2022
  • Figure 03: Peptide Therapeutics Market Size, by Route of Administration, 2022
  • Figure 04: Peptide Therapeutics Market share (%), by Route of Administration, 2022
  • Figure 05: Peptide Therapeutics Market Size, by Product Type, 2022
  • Figure 06: Peptide Therapeutics Market share (%), by Product Type, 2022
  • Figure 07: Peptide Therapeutics Market Size, by Types of Peptide, 2022
  • Figure 08: Peptide Therapeutics Market share (%), by Types of Peptide, 2022
  • Figure 09: Peptide Therapeutics Market Size, by Technology, 2022
  • Figure 10: Peptide Therapeutics Market share (%), by Technology, 2022
  • Figure 11: Peptide Therapeutics Market Size, by Manufacturing Type, 2022
  • Figure 12: Peptide Therapeutics Market share (%), by Manufacturing Type, 2022
  • Figure 13: Global Peptide Therapeutics Market, By Region (2022 and 2031)
  • Figure 14: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 16: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022
  • Figure 15: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 17: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2031
  • Figure 18: Global Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 19: Global Peptide Therapeutics Market Value (US$ Mn), by Innovative, 2023-2031
  • Figure 20: Global Peptide Therapeutics Market Value Share Analysis, by Innovative, 2022 and 2031
  • Figure 21: Global Peptide Therapeutics Market Value (US$ Mn), by Generic, 2023-2031
  • Figure 22: Global Peptide Therapeutics Market Value Share Analysis, by Generic, 2022 and 2031
  • Figure 23: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 24: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2022
  • Figure 25: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2031
  • Figure 26: Global Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 27: Global Peptide Therapeutics Market Value (US$ Mn), by Metabolic, 2023-2031
  • Figure 28: Global Peptide Therapeutics Market Value Share Analysis, by Metabolic, 2022 and 2031
  • Figure 29: Global Peptide Therapeutics Market Value (US$ Mn), by Oncology, 2023-2031
  • Figure 30: Global Peptide Therapeutics Market Value Share Analysis, by Oncology, 2022 and 2031
  • Figure 31: Global Peptide Therapeutics Market Value (US$ Mn), by Gastrointestinal, 2023-2031
  • Figure 32: Global Peptide Therapeutics Market Value Share Analysis, by Gastrointestinal, 2022 and 2031
  • Figure 33: Global Peptide Therapeutics Market Value (US$ Mn), by Cardiovascular, 2023-2031
  • Figure 34: Global Peptide Therapeutics Market Value Share Analysis, by Cardiovascular, 2022 and 2031
  • Figure 35: Global Peptide Therapeutics Market Value (US$ Mn), by Neurological, 2023-2031
  • Figure 36: Global Peptide Therapeutics Market Value Share Analysis, by Neurological, 2022 and 2031
  • Figure 37: Global Peptide Therapeutics Market Value (US$ Mn), by Others, 2023-2031
  • Figure 38: Global Peptide Therapeutics Market Value Share Analysis, by Others, 2022 and 2031
  • Figure 39: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2022 and 2031
  • Figure 40: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2022
  • Figure 41: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2031
  • Figure 42: Global Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration Type, 2023-2031
  • Figure 43: Global Peptide Therapeutics Market Value (US$ Mn), by Parenteral, 2023-2031
  • Figure 44: Global Peptide Therapeutics Market Value Share Analysis, by Parenteral, 2022 and 2031
  • Figure 45: Global Peptide Therapeutics Market Value (US$ Mn), by Oral, 2023-2031
  • Figure 46: Global Peptide Therapeutics Market Value Share Analysis, by Oral, 2022 and 2031
  • Figure 47: Global Peptide Therapeutics Market Value (US$ Mn), by Others, 2023-2031
  • Figure 48: Global Peptide Therapeutics Market Value Share Analysis, by Others, 2022 and 2031
  • Figure 49: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2022 and 2031
  • Figure 50: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2022
  • Figure 51: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2031
  • Figure 52: Global Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide Type, 2023-2031
  • Figure 53: Global Peptide Therapeutics Market Value (US$ Mn), by Native Peptides, 2023-2031
  • Figure 54: Global Peptide Therapeutics Market Value Share Analysis, by Native Peptides, 2022 and 2031
  • Figure 55: Global Peptide Therapeutics Market Value (US$ Mn), by Analog Peptides, 2023-2031
  • Figure 56: Global Peptide Therapeutics Market Value Share Analysis, by Analog Peptides, 2022 and 2031
  • Figure 57: Global Peptide Therapeutics Market Value (US$ Mn), by Heterologous Peptides, 2023-2031
  • Figure 58: Global Peptide Therapeutics Market Value Share Analysis, by Heterologous Peptides, 2022 and 2031
  • Figure 59: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2022 and 2031
  • Figure 60: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2022
  • Figure 61: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2031
  • Figure 62: Global Peptide Therapeutics Market Attractiveness Analysis, by Technology Type, 2023-2031
  • Figure 63: Global Peptide Therapeutics Market Value (US$ Mn), by Liquid Phase, 2023-2031
  • Figure 64: Global Peptide Therapeutics Market Value Share Analysis, by Liquid Phase, 2022 and 2031
  • Figure 65: Global Peptide Therapeutics Market Value (US$ Mn), by Solid Phase, 2023-2031
  • Figure 66: Global Peptide Therapeutics Market Value Share Analysis, by Solid Phase, 2022 and 2031
  • Figure 67: Global Peptide Therapeutics Market Value (US$ Mn), by Hybrid, 2023-2031
  • Figure 68: Global Peptide Therapeutics Market Value Share Analysis, by Hybrid, 2022 and 2031
  • Figure 69: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type , 2022 and 2031
  • Figure 70: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type , 2022
  • Figure 71: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type , 2031
  • Figure 72: Global Peptide Therapeutics Market Attractiveness Analysis, Manufacturing Type , 2023-2031
  • Figure 73: Global Peptide Therapeutics Market Value (US$ Mn), by In-house, 2023-2031
  • Figure 74: Global Peptide Therapeutics Market Value Share Analysis, by In-house, 2022 and 2031
  • Figure 75: Global Peptide Therapeutics Market Value (US$ Mn), by CMO, 2023-2031
  • Figure 76: Global Peptide Therapeutics Market Value Share Analysis, by CMO, 2022 and 2031
  • Figure 77: Global Peptide Therapeutics Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 78: Global Peptide Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 79: North America Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
  • Figure 80: North America Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 81: North America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 82: North America Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 83: North America Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 84: North America Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 85: North America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 86: North America Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 87: North America Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 88: North America Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031
  • Figure 89: North America Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031
  • Figure 90: North America Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 91: North America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 92: North America Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
  • Figure 93: North America Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
  • Figure 94: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
  • Figure 95: Europe Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 96: Europe Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 97: Europe Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 98: Europe Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 99: Europe Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 100: Europe Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 101: Europe Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 102: Europe Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 103: Europe Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031
  • Figure 104: Europe Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031
  • Figure 105: Europe Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 106: Europe Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 107: Europe Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
  • Figure 108: Europe Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
  • Figure 109: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
  • Figure 110: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 111: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 112: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 113: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 114: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 115: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 116: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 117: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 118: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031
  • Figure 119: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031
  • Figure 120: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 121: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 122: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
  • Figure 123: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
  • Figure 124: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
  • Figure 125: Latin America Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 126: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 127: Latin America Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 128: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 129: Latin America Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 130: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 131: Latin America Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 132: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 133: Latin America Peptide Therapeutics Market Value Share Analysis, by Type of Peptide, 2022 and 2031
  • Figure 134: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Type of Peptide, 2023-2031
  • Figure 135: Latin America Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 136: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 137: Latin America Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
  • Figure 138: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
  • Figure 139: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
  • Figure 140: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 141: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 142: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 143: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 144: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 145: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 146: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 147: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 148: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Type of Peptide, 2022 and 2031
  • Figure 149: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Type of Peptide, 2023-2031
  • Figure 150: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 151: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 152: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
  • Figure 153: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
  • Figure 154: Global Peptide Therapeutics Market: Company Share Analysis, 2022
目次
Product Code: TMRGL418

Peptide Therapeutics Market - Scope of Report

TMR's report on the global peptide therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global peptide therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the peptide therapeutics market.

Market Snapshot
Market Value in 2023US$ 37.8 Bn
Market Value in 2031US$ 85.9 Bn
CAGR9.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peptide therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peptide therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peptide therapeutics market.

The report delves into the competitive landscape of the global peptide therapeutics market. Key players operating in the global peptide therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peptide therapeutics market profiled in this report.

Key Questions Answered in Global peptide therapeutics Market Report:

  • What is the sales/revenue generated by peptide therapeutics across all regions during the forecast period?
  • What are the opportunities in the global peptide therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Peptide Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global peptide therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peptide therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peptide therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Peptide Therapeutics Market

4. Market Overview

  • 4.1. Introduction
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Peptide Therapeutics Market Analysis and Forecasts, 2023 - 2031

5. Key Insights

  • 5.1. FDA-approved Peptide Therapeutics in 2022
  • 5.2. Peptide Drugs Approved Since 2000, with their Targets and Indications
  • 5.3. White Space Analysis
  • 5.4. Porter's Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Peptide Drugs Chemical Structure Trend Analysis
  • 5.7. Separation Media Used for Peptide Drugs
  • 5.8. COVID-19 Impact Analysis

6. Global Peptide Therapeutics Market Analysis and Forecasts, By Product Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Product Type, 2023 - 2031
    • 6.3.1. Innovative
    • 6.3.2. Generic
  • 6.4. Market Attractiveness By Product Type

7. Global Peptide Therapeutics Market Analysis and Forecasts, By Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Application, 2023 - 2031
    • 7.3.1. Metabolic
    • 7.3.2. Oncology
    • 7.3.3. Gastrointestinal
    • 7.3.4. Cardiovascular
    • 7.3.5. Neurological
    • 7.3.6. Others
  • 7.4. Market Attractiveness By Application

8. Global Peptide Therapeutics Market Analysis and Forecasts, By Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Route of Administration, 2023 - 2031
    • 8.3.1. Parenteral
    • 8.3.2. Oral
    • 8.3.3. Others
  • 8.4. Market Attractiveness By Route of Administration

9. Global Peptide Therapeutics Market Analysis and Forecasts, By Types of Peptide

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By Types of Peptide, 2023 - 2031
    • 9.3.1. Native Peptides
    • 9.3.2. Analog Peptides
    • 9.3.3. Heterologous Peptides
  • 9.4. Market Attractiveness By Types of Peptide

10. Global Peptide Therapeutics Market Analysis and Forecasts, By Technology

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast By Technology, 2023 - 2031
    • 10.3.1. Liquid Phase
    • 10.3.2. Solid Phase
    • 10.3.3. Hybrid
  • 10.4. Market Attractiveness By Technology

11. Global Peptide Therapeutics Market Analysis and Forecasts, By Manufacturing Type

  • 11.1. Introduction & Definition
  • 11.2. Key Findings / Developments
  • 11.3. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 11.3.1. In-house
    • 11.3.2. CMO
  • 11.4. Market Attractiveness By Manufacturing Type

12. Global Peptide Therapeutics Market Analysis and Forecasts, By Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast By Region
    • 12.2.1. North America
    • 12.2.2. Europe
    • 12.2.3. Asia Pacific
    • 12.2.4. Latin America
    • 12.2.5. Middle East & Africa
  • 12.3. Market Attractiveness By Country/Region

13. North America Peptide Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Product Type,2023 - 2031
    • 13.2.1. Innovative
    • 13.2.2. Generic
  • 13.3. Market Value Forecast By Application,2023 - 2031
    • 13.3.1. Metabolic
    • 13.3.2. Oncology
    • 13.3.3. Gastrointestinal
    • 13.3.4. Cardiovascular
    • 13.3.5. Neurological
    • 13.3.6. Others
  • 13.4. Market Value Forecast By Route of Administration,2023 - 2031
    • 13.4.1. Parenteral
    • 13.4.2. Oral
    • 13.4.3. Others
  • 13.5. Market Value Forecast By Types of Peptide,2023 - 2031
    • 13.5.1. Native Peptides
    • 13.5.2. Analog Peptides
    • 13.5.3. Heterologous Peptides
  • 13.6. Market Value Forecast By Technology,2023 - 2031
    • 13.6.1. Liquid Phase
    • 13.6.2. Solid Phase
    • 13.6.3. Hybrid
  • 13.7. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 13.7.1. In-house
    • 13.7.2. CMO
  • 13.8. Market Value Forecast By Country,2023 - 2031
    • 13.8.1. U.S.
    • 13.8.2. Canada
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Product Type
    • 13.9.2. By Application
    • 13.9.3. By Route of Administration
    • 13.9.4. By Types of Peptide
    • 13.9.5. By Technology
    • 13.9.6. By Manufacturing Type
    • 13.9.7. By Country

14. Europe Peptide Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Product Type,2023 - 2031
    • 14.2.1. Innovative
    • 14.2.2. Generic
  • 14.3. Market Value Forecast By Application,2023 - 2031
    • 14.3.1. Metabolic
    • 14.3.2. Oncology
    • 14.3.3. Gastrointestinal
    • 14.3.4. Cardiovascular
    • 14.3.5. Neurological
    • 14.3.6. Others
  • 14.4. Market Value Forecast By Route of Administration,2023 - 2031
    • 14.4.1. Parenteral
    • 14.4.2. Oral
    • 14.4.3. Others
  • 14.5. Market Value Forecast By Types of Peptide,2023 - 2031
    • 14.5.1. Native Peptides
    • 14.5.2. Analog Peptides
    • 14.5.3. Heterologous Peptides
  • 14.6. Market Value Forecast By Technology,2023 - 2031
    • 14.6.1. Liquid Phase
    • 14.6.2. Solid Phase
    • 14.6.3. Hybrid
  • 14.7. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 14.7.1. In-house
    • 14.7.2. CMO
  • 14.8. Market Value Forecast By Country,2023 - 2031
    • 14.8.1. Germany
    • 14.8.2. U.K.
    • 14.8.3. France
    • 14.8.4. Spain
    • 14.8.5. Italy
    • 14.8.6. Rest of Europe
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Product Type
    • 14.9.2. By Application
    • 14.9.3. By Route of Administration
    • 14.9.4. By Types of Peptide
    • 14.9.5. By Technology
    • 14.9.6. By Manufacturing Type
    • 14.9.7. By Country

15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Product Type,2023 - 2031
    • 15.2.1. Innovative
    • 15.2.2. Generic
  • 15.3. Market Value Forecast By Application,2023 - 2031
    • 15.3.1. Metabolic
    • 15.3.2. Oncology
    • 15.3.3. Gastrointestinal
    • 15.3.4. Cardiovascular
    • 15.3.5. Neurological
    • 15.3.6. Others
  • 15.4. Market Value Forecast By Route of Administration,2023 - 2031
    • 15.4.1. Parenteral
    • 15.4.2. Oral
    • 15.4.3. Others
  • 15.5. Market Value Forecast By Types of Peptide,2023 - 2031
    • 15.5.1. Native Peptides
    • 15.5.2. Analog Peptides
    • 15.5.3. Heterologous Peptides
  • 15.6. Market Value Forecast By Technology,2023 - 2031
    • 15.6.1. Liquid Phase
    • 15.6.2. Solid Phase
    • 15.6.3. Hybrid
  • 15.7. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 15.7.1. In-house
    • 15.7.2. CMO
  • 15.8. Market Value Forecast By Country,2023 - 2031
    • 15.8.1. China
    • 15.8.2. Japan
    • 15.8.3. India
    • 15.8.4. Australia & New Zealand
    • 15.8.5. Rest of Asia Pacific
  • 15.9. Market Attractiveness Analysis
    • 15.9.1. By Product Type
    • 15.9.2. By Application
    • 15.9.3. By Route of Administration
    • 15.9.4. By Types of Peptide
    • 15.9.5. By Technology
    • 15.9.6. By Manufacturing Type
    • 15.9.7. By Country

16. Latin America Peptide Therapeutics Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast By Product Type,2023 - 2031
    • 16.2.1. Innovative
    • 16.2.2. Generic
  • 16.3. Market Value Forecast By Application,2023 - 2031
    • 16.3.1. Metabolic
    • 16.3.2. Oncology
    • 16.3.3. Gastrointestinal
    • 16.3.4. Cardiovascular
    • 16.3.5. Neurological
    • 16.3.6. Others
  • 16.4. Market Value Forecast By Route of Administration,2023 - 2031
    • 16.4.1. Parenteral
    • 16.4.2. Oral
    • 16.4.3. Others
  • 16.5. Market Value Forecast By Types of Peptide,2023 - 2031
    • 16.5.1. Native Peptides
    • 16.5.2. Analog Peptides
    • 16.5.3. Heterologous Peptides
  • 16.6. Market Value Forecast By Technology,2023 - 2031
    • 16.6.1. Liquid Phase
    • 16.6.2. Solid Phase
    • 16.6.3. Hybrid
  • 16.7. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 16.7.1. In-house
    • 16.7.2. CMO
  • 16.8. Market Value Forecast By Country,2023 - 2031
    • 16.8.1. Brazil
    • 16.8.2. Mexico
    • 16.8.3. Rest of Latin America
  • 16.9. Market Attractiveness Analysis
    • 16.9.1. By Product Type
    • 16.9.2. By Application
    • 16.9.3. By Route of Administration
    • 16.9.4. By Types of Peptide
    • 16.9.5. By Technology
    • 16.9.6. By Manufacturing Type
    • 16.9.7. By Country

17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast

  • 17.1. Introduction
    • 17.1.1. Key Findings
  • 17.2. Market Value Forecast By Product Type,2023 - 2031
    • 17.2.1. Innovative
    • 17.2.2. Generic
  • 17.3. Market Value Forecast By Application,2023 - 2031
    • 17.3.1. Metabolic
    • 17.3.2. Oncology
    • 17.3.3. Gastrointestinal
    • 17.3.4. Cardiovascular
    • 17.3.5. Neurological
    • 17.3.6. Others
  • 17.4. Market Value Forecast By Route of Administration,2023 - 2031
    • 17.4.1. Parenteral
    • 17.4.2. Oral
    • 17.4.3. Others
  • 17.5. Market Value Forecast By Types of Peptide,2023 - 2031
    • 17.5.1. Native Peptides
    • 17.5.2. Analog Peptides
    • 17.5.3. Heterologous Peptides
  • 17.6. Market Value Forecast By Technology,2023 - 2031
    • 17.6.1. Liquid Phase
    • 17.6.2. Solid Phase
    • 17.6.3. Hybrid
  • 17.7. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 17.7.1. In-house
    • 17.7.2. CMO
  • 17.8. Market Value Forecast By Country,2023 - 2031
    • 17.8.1. GCC Countries
    • 17.8.2. South Africa
    • 17.8.3. Rest of Middle East & Africa
  • 17.9. Market Attractiveness Analysis
    • 17.9.1. By Product Type
    • 17.9.2. By Application
    • 17.9.3. By Route of Administration
    • 17.9.4. By Types of Peptide
    • 17.9.5. By Technology
    • 17.9.6. By Manufacturing Type
    • 17.9.7. By Country

18. Competition Landscape

  • 18.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 18.2. Market Share Analysis By Company (2022)
  • 18.3. Company Profiles
    • 18.3.1. Amgen, Inc.
      • 18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. Financial Overview
      • 18.3.1.4. SWOT Analysis
      • 18.3.1.5. Strategic Overview
    • 18.3.2. Sachem Holding AG
      • 18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. Financial Overview
      • 18.3.2.4. SWOT Analysis
      • 18.3.2.5. Strategic Overview
    • 18.3.3. Eli Lilly and Company
      • 18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. Financial Overview
      • 18.3.3.4. SWOT Analysis
      • 18.3.3.5. Strategic Overview
    • 18.3.4. F. Hoffmann-La Roche Ltd.
      • 18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. Financial Overview
      • 18.3.4.4. SWOT Analysis
      • 18.3.4.5. Strategic Overview
    • 18.3.5. GlaxoSmithKline plc
      • 18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. Financial Overview
      • 18.3.5.4. SWOT Analysis
      • 18.3.5.5. Strategic Overview
    • 18.3.6. Novartis AG
      • 18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. Financial Overview
      • 18.3.6.4. SWOT Analysis
      • 18.3.6.5. Strategic Overview
    • 18.3.7. Pfizer, Inc.
      • 18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.7.2. Product Portfolio
      • 18.3.7.3. Financial Overview
      • 18.3.7.4. SWOT Analysis
      • 18.3.7.5. Strategic Overview
    • 18.3.8. Sanofi
      • 18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.8.2. Product Portfolio
      • 18.3.8.3. Financial Overview
      • 18.3.8.4. SWOT Analysis
      • 18.3.8.5. Strategic Overview
    • 18.3.9. Takeda Pharmaceutical Company Limited
      • 18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.9.2. Product Portfolio
      • 18.3.9.3. Financial Overview
      • 18.3.9.4. SWOT Analysis
      • 18.3.9.5. Strategic Overview
    • 18.3.10. Teva Pharmaceutical Industries Ltd.
      • 18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.10.2. Product Portfolio
      • 18.3.10.3. Financial Overview
      • 18.3.10.4. SWOT Analysis
      • 18.3.10.5. Strategic Overview